Mutational Analysis of Sigma-1 Receptor’s Role in Synaptic Stability
Open accessAbstract
Sigma-1 receptor (S1R) is an endoplasmic reticulum (ER) resident transmembrane protein. In our previous experiments we demonstrated neuroprotective effects of pridopidine, an agonist of S1R, in cellular and animal models of Huntington’s (HD) and Alzheimer’s (AD) disease. Consistent with previous observations, deletion of endogenous S1R with CRISPR/Cas9 in cultured hippocampal neurons resulted in fewer mushroom-shaped dendritic spines. Overexpression of human S1R restored mushroom spine density to control levels. In contrast, overexpression of S1R with the ∆31-50 deletion (linked to distal hereditary motor neuropathy) or the E102Q mutation (linked to amyotrophic lateral sclerosis) destabilized mushroom spines. Recently a crystal structure of S1R was determined in lipidic cubic phase. In the present study we took an advantage of this structural information and performed docking studies with pridopidine and the S1R structural model. We generated a series of S1R point mutations based on residues predicted to be involved in direct association with pridopidine. We discovered that all ligand binding-site mutants were able to compensate for loss of endogenous S1R. However, most of these mutants were not able to support pridopidine-induced rescue of mushroom spines in presenilin-1 mutant cultures. Our mutational analysis was in agreement with in silico docking based on the published S1R crystal structure, with an exception of R119 residue. Our data also suggests that basal S1R activity is required for mature spine stability, whereas agonist-mediated S1R activity is required for stabilization of mushroom spines in the context of disease-causing mutations
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DMT exhibits, besides the 5-HT2AR, also high affinity for the S1R, which is highly expressed in the hippocampus and is a stimulator of synaptic plasticity.
“DMT exhibits, besides the 5-HT2AR, also high affinity for the S1R, which is highly expressed in the hippocampus and is a stimulator of synaptic plasticity (99–101).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [101]
The Introduction says S1R regulates synaptic plasticity, and the Discussion describes its role in maintaining spines in hippocampal neurons. The passages do not establish that S1R is highly expressed in the hippocampus. Searches for DMT and N,N-dimethyltryptamine found no support for the claimed high affinity for S1R or the comparison with 5-HT2AR. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,260 · see citing works
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,745 · see citing works
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654 · see citing works
Guo, Q., Fu, W., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Nature Medicine · doi:10.1038/4789 · Cited by 489 · see citing works
Crystal structure of the human σ1 receptor
Schmidt, H. R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., & Kruse, A. C. (2016) · Nature · doi:10.1038/nature17391 · Cited by 482 · see citing works
A mutation in sigma‐1 receptor causes juvenile amyotrophic lateral sclerosis
Al-Saif, A. M., Al-Mohanna, F. A., & Bohlega, S. (2011) · Annals of Neurology · doi:10.1002/ana.22534 · Cited by 430 · see citing works
The Sigma Receptor as a Ligand-Regulated Auxiliary Potassium Channel Subunit
Aydar, E., Palmer, C. P., Klyachko, V. A., & Jackson, M. B. (2002) · Neuron · doi:10.1016/s0896-6273(02)00677-3 · Cited by 400 · see citing works
Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system
Alonso, G., Phan, V. L., Guillemain, I., Saunier, M., Legrand, A., Anoal, M., & Maurice, T. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00014-2 · Cited by 367 · see citing works
Meunier, J., Ieni, J. R., & Maurice, T. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706927 · Cited by 289 · see citing works
Sun, S., Zhang, H., Liu, J., Александровна, П. Е., Xu, N., Feske, S., White, C. L., & Борисович, Б. И. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.019 · Cited by 273 · see citing works
Mitochondria‐associated membrane collapse is a common pathomechanism in SIGMAR1‐ and SOD1‐linked ALS
Watanabe, S., Ilieva, H. S., Tamada, H., Nomura, H., Komine, O., Endo, F., Jin, S., Mancías, P., Kiyama, H., & Yamanaka, K. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606403 · Cited by 231 · see citing works
Francardo, V., Bez, F., Wieloch, T. W., Nissbrandt, H., Ruscher, K., & Cenci, M. A. (2014) · Brain · doi:10.1093/brain/awu107 · Cited by 207 · see citing works
Luty, A. A., Kwok, J. B., Dobson‐Stone, C., Loy, C. T., Coupland, K., Karlström, H., Sobów, T., Tchorzewska, J., Maruszak, A., Barcikowska, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22274 · Cited by 196 · see citing works
Martina, M., B.‐Turcotte, M., Halman, S., & Bergeron, R. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.116178 · Cited by 187 · see citing works
Zhang, H., Wu, L., Pchitskaya, E. I., Zakharova, O. A., Saito, T., Saido, T. C., & Борисович, Б. И. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1034-15.2015 · Cited by 181 · see citing works
Pal, A., Fontanilla, D., Gopalakrishnan, A., Chae, Y.-K., Markley, J. L., & Ruoho, A. E. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.030 · Cited by 177 · see citing works
Low density of sigma1 receptors in early Alzheimer’s disease
Mishina, M., Ohyama, M., Ishii, K., Kitamura, S., Kimura, Y., Oda, K.-I., Kawamura, K., Sasaki, T., Kobayashi, S., Katayama, Y., et al. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0094-z · Cited by 172 · see citing works
Tsai, S., Hayashi, T., Harvey, B. K., Wang, Y., Wu, W. W., Shen, R., Zhang, Y., Becker, K. G., Hoffer, B. J., & Su, T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909089106 · Cited by 160 · see citing works
Structural basis for σ1 receptor ligand recognition
Schmidt, H. R., Betz, R. M., Dror, R. O., & Kruse, A. C. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0137-2 · Cited by 155 · see citing works
Villard, V., Espallergues, J., Keller, E., Vamvakides, A., & Maurice, T. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379286 · Cited by 139 · see citing works
Rijsketic, D. R., Wu, J., Geva, M., Kusko, R. L., Grossman, I., Hayden, M. R., & Борисович, Б. И. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.10.006 · Cited by 132 · see citing works
Wu, J., Ryskamp, D. A., Liang, X., Egorova, P. A., Zakharova, O. A., Hung, G., & Борисович, Б. И. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1038-15.2016 · Cited by 131 · see citing works
Self-citationNeuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity
Marrazzo, A., Caraci, F., Salinaro, E. T., Su, T., Copani, A., & Ronsisvalle, G. (2005) · Neuroreport · doi:10.1097/00001756-200508010-00018 · Cited by 120 · see citing works
Mishra, A. K., Mavlyutov, T. A., Singh, D. R., Biener, G., Yang, J., Oliver, J. A., Ruoho, A. E., & Raicu, V. (2014) · Biochemical Journal · doi:10.1042/bj20141321 · Cited by 113 · see citing works
The Oligomeric States of the Purified Sigma-1 Receptor Are Stabilized by Ligands
Gromek, K. A., Suchy, F. P., Meddaugh, H. R., Wrobel, R. L., LaPointe, L. M., Chu, U. B., Primm, J. G., Ruoho, A. E., Senes, A., & Fox, B. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537993 · Cited by 106 · see citing works
Lack of sigma-1 receptor exacerbates ALS progression in mice
Mavlyutov, T. A., Epstein, M. L., Verbny, Y., Huerta, M. S., Zaitoun, I. S., Ziskind‐Conhaim, L., & Ruoho, A. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.035 · Cited by 105 · see citing works
Villard, V., Espallergues, J., Keller, E., Alkam, T., Nitta, A., Yamada, K., Nabeshima, T., Vamvakides, A., & Maurice, T. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.212 · Cited by 105 · see citing works
Goguadze, N., Zhuravliova, E., Morin, D., Mikeladze, D., & Maurice, T. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9838-2 · Cited by 105 · see citing works
Jansen, K. L. R., Faull, R. L. M., Storey, P., & Leslie, R. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)91441-t · Cited by 103 · see citing works
Dreser, A., Vollrath, J. T., Sechi, A. S., Johann, S., Roos, A., Yamoah, A., Katona, I., Bohlega, S., Wiemuth, D., Tian, Y., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.88 · Cited by 101 · see citing works
Gregianin, E., Pallafacchina, G., Zanin, S., Crippa, V., Rusmini, P., Poletti, A., Fang, M., Li, Z., Diano, L., Petrucci, A., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw220 · Cited by 97 · see citing works
AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease
Fisher, A., Борисович, Б. И., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000440864 · Cited by 82 · see citing works
Self-citationRoldan, J. O., Ossa, F., & Schnell, J. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.450379 · Cited by 81 · see citing works
A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy
Li, X., Hu, Z., Liu, L., Xie, Y., Zhan, Y., Zi, X., Wang, J., Wu, L., Xia, K., Tang, B., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001680 · Cited by 81 · see citing works
Tsai, S., Pokrass, M. J., Klauer, N. R., Nohara, H., & Su, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422001112 · Cited by 77 · see citing works
Association between a variant of the sigma-1 receptor gene and Alzheimer's disease
Fehér, Á., Juhász, A., László, A., Kalman, J. L., Pákáski, M., Kalman, J. L., & Janka, Z. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.04.046 · Cited by 75 · see citing works
Hong, W. C., Yano, H., Hiranita, T., Chin, F. T., McCurdy, C. R., Su, T., Amara, S. G., & Katz, J. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.774075 · Cited by 73 · see citing works
The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor
Sahlholm, K., Århem, P., Fuxé, K., & Marcellino, D. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.3 · Cited by 71 · see citing works
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor
Eddings, C. R., Arbez, N., Akimov, S., Geva, M., Hayden, M. R., & Ross, C. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.05.009 · Cited by 70 · see citing works
Rijsketic, D. R., Wu, L., Wu, J., Kim, D. B., Rammes, G., Geva, M., Hayden, M. R., & Борисович, Б. И. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.12.022 · Cited by 69 · see citing works
Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor.
Mavlyutov, T. A., Nickells, R. W., & Guo, L. (2011) · PubMed Central · Cited by 66 · see citing works
Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases
Maurice, T., & Goguadze, N. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_15 · Cited by 62 · see citing works
Smith-Dijak, A., Nassrallah, W. B., Zhang, L. Y. J., Geva, M., Hayden, M. R., & Raymond, L. A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00209 · Cited by 58 · see citing works
Sigma receptor ligands protect human retinal cells against oxidative stress
Bucolo, C., Drago, F., Lin, L.-R., & Reddy, V. N. (2006) · Neuroreport · doi:10.1097/01.wnr.0000199469.21734.e1 · Cited by 58 · see citing works
Huang, Y. M., Zheng, L., Halliday, G. M., Dobson‐Stone, C., Wang, Y., Tang, H., Cao, L., Deng, Y., Wang, G., Zhang, Y., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511797633232 · Cited by 58 · see citing works
Pal, A., Chu, U. B., Ramachandran, S., Grawoig, D., Guo, L., Hajipour, A. R., & Ruoho, A. E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802192200 · Cited by 56 · see citing works
A Variant of the Sigma Receptor Type-1 Gene Is a Protective Factor for Alzheimer Disease
Uchida, N., Ujike, H., Tanaka, Y., Sakai, A., Yamamoto, M., Fujisawa, Y., Kanzaki, A., & Kuroda, S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200512000-00005 · Cited by 56 · see citing works
Sahlholm, K., Sijbesma, J. W. A., Maas, B., Kwizera, C., Marcellino, D. J., Ramakrishnan, N. K., Dierckx, R., Elsinga, P. H., & van Waarde, A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3997-8 · Cited by 55 · see citing works
Miki, Y., Tanji, K., Mori, F., & Wakabayashi, K. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.005 · Cited by 54 · see citing works
Mavlyutov, T. A., Yang, H. M., Epstein, M. L., Ruoho, A. E., Yang, J., & Guo, L. (2017) · Oncotarget · doi:10.18632/oncotarget.17906 · Cited by 54 · see citing works
Maurice, T., Volle, J., Strehaïano, M., Crouzier, L., Pereira, C., Kaloyanov, N., Virieux, D., & Pirat, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.026 · Cited by 54 · see citing works
Wu, J., Rijsketic, D. R., Birnbaumer, L., & Борисович, Б. И. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170266 · Cited by 54 · see citing works
Diabetes accelerates retinal ganglion cell dysfunction in mice lacking sigma receptor 1.
Ha, Y., SAUL, A. B., Tawfik, A. M., Zorrilla, E. P., Ganapathy, V., & Smith, S. B. (2012) · Europe PMC (PubMed Central) · Cited by 52 · see citing works
Brune, S., Schepmann, D., Klempnauer, K., Marson, D., Col, V. D., Laurini, E., Fermeglia, M., Wünsch, B., & Pricl, S. (2014) · Biochemistry · doi:10.1021/bi401575g · Cited by 50 · see citing works
ABS–Scan: In silico alanine scanning mutagenesis for binding site residues in protein–ligand complex
Anand, P., Nagarajan, D., Mukherjee, S., & Chandra, N. R. (2014) · F1000Research · doi:10.12688/f1000research.5165.1 · Cited by 47 · see citing works
Structure of the σ1 Receptor and Its Ligand Binding Site
Brune, S., Pricl, S., & Wünsch, B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400660u · Cited by 46 · see citing works
Ullah, M. I., Ahmad, A., Raza, S. I., Amar, A., Ali, A., Bhatti, A., John, P. C. L., Mohyuddin, A., Ahmad, W., & Hassan, M. J. (2015) · Neurogenetics · doi:10.1007/s10048-015-0453-1 · Cited by 46 · see citing works
Wang, L., Eldred, J. A., Sidaway, P., Sanderson, J., Smith, A. J. O., Bowater, R. P., Reddan, J. R., & Wormstone, I. M. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.09.005 · Cited by 46 · see citing works
Yamamoto, T., Takeuchi, H., Kanematsu, T., Allen-Baume, V., Yagisawa, H., Kikkawa, U., Watanabe, Y., Nakasima, A., Katan, M., & Hirata, M. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00786.x · Cited by 42 · see citing works
Mavylutov, T., Chen, X., Guo, L., & Yang, J. (2017) · Protein & Cell · doi:10.1007/s13238-017-0468-5 · Cited by 41 · see citing works
SIGMAR1 mutation associated with autosomal recessive Silver-like syndrome
Horga, A., Tomaselli, P. J., Gonzalez, M., Laurá, M., Francesco Muntoni, A., Manzur, A. Y., Hanna, M. G., Blake, J. C., Houlden, H., Zuchner, S. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003212 · Cited by 40 · see citing works
Maruszak, A., Safranow, K., Gacia, M., Gabryelewicz, T., Słowik, A., Styczyńska, M., Pepłońska, B., Golan, M. P., Żekanowski, C., & Barcikowska, M. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000101990 · Cited by 36 · see citing works
Roldan, J. O., Ossa, F., Amin, N., & Schnell, J. R. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.01.033 · Cited by 35 · see citing works
Amyloid toxicity is enhanced after pharmacological or genetic invalidation of the σ1 receptor
Maurice, T., Strehaïano, M., Duhr, F., & Chevallier, N. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.010 · Cited by 34 · see citing works
Aberrant Subcellular Dynamics of Sigma-1 Receptor Mutants Underlying Neuromuscular Diseases
Wong, A. Y. C., Hristova, E., Ahlskog, N., Tassé, L.-A., Ngsee, J. K., Chudalayandi, P., & Bergeron, R. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104018 · Cited by 29 · see citing works
Dalwadi, D. A., Kim, S., & Schetz, J. A. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.02.003 · Cited by 29 · see citing works
ABS–Scan: In silico alanine scanning mutagenesis for binding site residues in protein–ligand complex
Anand, P., Nagarajan, D., Mukherjee, S., et al. (2014) · F1000Research · doi:10.12688/f1000research.5165.2 · Cited by 29 · see citing works
Mutations in UBQLN2 and SIGMAR1 genes are rare in Korean patients with amyotrophic lateral sclerosis
Kim, H., Kwon, M., Choi, W.-J., Oh, K., Oh, S., Ki, C., & Kim, S. H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.001 · Cited by 28 · see citing works
A Review of the Human Sigma-1 Receptor Structure
Ossa, F., Schnell, J. R., & Roldan, J. O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-50174-1_3 · Cited by 28 · see citing works
A Variant of the Sigma Receptor Type-1 Gene Is a Protective Factor for Alzheimer Disease
Uchida, N. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.12.1062 · Cited by 25 · see citing works
Human sigma-1 receptor bound to (+)-pentazocine
Schmidt, H. R., & Kruse, A. C. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6dk1/pdb · Cited by 24 · see citing works
Flagged first, then by citations
2 of the 73 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269 · see citing works
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
Goguadze, N., Zhuravliova, E., Morin, D., Mikeladze, D., & Maurice, T. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9838-2 · Cited by 105 · see citing works
Crouzier, L., Danese, A., Yasui, Y., Richard, É. M., Liévens, J.-C., Patergnani, S., Couly, S., Diez, C., Denus, M., Cubedo, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abh3763 · Cited by 73 · see citing works
Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis
Herrando‐Grabulosa, M., Gaja‐Capdevila, N., Vela, J. M., & Navarro, X. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15224 · Cited by 63 · see citing works
CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review
Barman, N. C., Khan, M. N. M., Islam, M., Nain, Z., Roy, R. K., Haque, A., & BARMAN, S. K. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00218-z · Cited by 64 · see citing works
Wu, N., Ye, Y., Wan, B.-B., Yu, Y.-D., Liu, C., & Chen, Q. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02524-5 · Cited by 55 · see citing works
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S. J., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46 · see citing works
Badawi, G. A., Shokr, M. M., Elshazly, S. M., Zaki, H. F., & Mohamed, A. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176851 · Cited by 39 · see citing works
Chaperone Sigma1R and Antidepressant Effect
Воронин, М. В., Vakhitova, Y. V., & Середенин, С. Б. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197088 · Cited by 40 · see citing works
Shenkman, M., Geva, M., Gershoni‐Emek, N., Hayden, M. R., & Lederkremer, G. Z. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15366 · Cited by 31 · see citing works
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 33 · see citing works
Crouzier, L., Denus, M., Richard, É. M., Tavernier, A., Diez, C., Cubedo, N., Maurice, T., & Delprat, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011049 · Cited by 25 · see citing works
Involvement of Chaperone Sigma1R in the Anxiolytic Effect of Fabomotizole
Воронин, М. В., Vakhitova, Y. V., Tsypysheva, I. P., Tsypyshev, D. O., Rybina, I. V., Kurbanov, R. D., Абрамова, Е. В., & Середенин, С. Б. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115455 · Cited by 22 · see citing works
Estévez-Silva, H. M., Cuesto, G., Romero, N., Armas, J. M. B., Acevedo‐Arozena, A., Acebes, Á., & Marcellino, D. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01280-1 · Cited by 19 · see citing works
Gene Editing and Alzheimer's Disease: Is There Light at the End of the Tunnel?
Stepanichev, M. Y. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.00004 · Cited by 16 · see citing works
CRISPR/Cas9 Gene Editing: A Novel Approach Towards Alzheimer's Disease Treatment
Tripathi, S., Sharma, Y., Rane, R. A., & Kumar, D. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273283786240408034408 · Cited by 11 · see citing works
The ALS-Related σ1R E102Q Mutant Eludes Ligand Control and Exhibits Anomalous Response to Calcium
Rodríguez-Muñoz, M., Cortés‐Montero, E., Garzón, J., & Sánchez‐Blázquez, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197339 · Cited by 8 · see citing works
Djebari, S., Jiménez‐Herrera, R., Iborra‐Lázaro, G., Jiménez‐Díaz, L., & Navarro‐López, J. D. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117914 · Cited by 5 · see citing works
Updates on Endoplasmic Reticulum
Favero, G. (2022) · Biochemistry · doi:10.5772/intechopen.100952 · Cited by 2 · see citing works
Mitochondria-Endoplasmic Reticulum Interaction in Central Neurons
Kushnireva, L., & Korkotian, E. (2022) · Biochemistry · doi:10.5772/intechopen.105738 · Cited by 2 · see citing works
- Authors
- Ryskamp, D. A., Zhemkov, V., & Bezprozvanny, I.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Zhemkov, Vladimir
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-09-19
- Volume
- 13
- Pages
- 1012-1012
- ISSN
- 1662-453X (ISSN-L)
- PMC
- PMC6761230
- OpenAlex
- W2972017733
- Cited by
- 21
- References
- 73
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 4 · 2021: 5 · 2020: 7 · 2017: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute of Neurological Disorders and Stroke (NS056224)
- National Institute on Aging
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- sigma-1 receptor, synaptic stability, pridopidine, ligand binding sites, point mutations, molecular docking, presenilin 1, Alzheimer's disease, Huntington's disease, distal hereditary motor neuropathy, amyotrophic lateral sclerosis, endoplasmic reticulum, hippocampal neurons, neuroprotection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
